lundi 4 juin 2018

Onco Actu du 4 juin 2018 - Spécial ASCO

5.5 ASCO

ASCO Applauds NCI Announcement on Increased Funding for National Clinical Trials Network, Continued Commitment to Clinical Trials [ASCO]

ASCO Welcomes FDA Strategy for Advancing Cancer Treatments [ASCO]

FDA chief outlines new ways to speed cancer drug approvals [Reuters]

5.5.1 ASCO (général)

ASCO Highlights for Sunday June 3, 2018 [OBR Blog]

ASCO Highlights for Saturday, June 2, 2018 [OBR Blog]

ASCO 2018 news briefing: kinder treatment for breast and kidney cancer, plus lung immunotherapy progress [Cancer Research UK]

5.5.10 ASCO (hémato)

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy [Novartis]

Moxetumomab pasudotox pivotal data in patients with previously-treated hairy cell leukaemia presented at the 2018 ASCO meeting [AstraZeneca]

Stanford spinout Forty Seven arrives at ASCO with a snapshot of promising CD47 data — and a $115M IPO in hand [EndPoints]

5.5.12 ASCO (médico-éco)

Treatment for Colorectal Cancer in Washington State Costs Twice as Much as in Neighboring Area of Canada, Despite No Difference in Survival [ASCO]

Canada colon cancer drugs half the price, same survival as U.S.: study [Reuters]

5.5.13 ASCO (divers)

Geriatric Assessment Improves Communication Between Oncologists and Older Patients [ASCO]

5.5.14 ASCO (vessie)

Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy [Seattle Genetics]

Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer [Janssen]

5.5.15 ASCO (biopsies liquides)

Grail’s cancer blood test shows ‘proof of principle,’ but challenges remain [STAT]

Blood Test Shows Potential as a Detection Tool for Early-Stage Lung Cancer [ASCO]

Biotech Firm Grail Takes The First Steps In Its Quest For A Blood Test For Cancer [Forbes]

A Blood-Based Cancer Test Gets Its First Results [Wired]

Grail blood test shows promise in early detection of lung cancer [Reuters]

5.5.16 ASCO (médecine de précision)

Genomic Study Finds Lynch Syndrome Is Common Among People With MSI-High Tumors [ASCO]

Matching Treatment to Genetic Changes in the Tumor Improves Survival Across Multiple Cancer Types [ASCO]

Gene sequencing study finds new cancers linked with Lynch syndrome [Reuters] ASCO (médecine de précision-TRK/RET)

Loxo Oncology shows high tumor response rates with second genetically targeted cancer drug [STAT]

Loxo Unveils More Data, Paves a Path Forward In Precision Oncology [Xconomy]

Loxo Scores A Success With Second Targeted Cancer Drug [Forbes]

Spurring move to personalized therapies, Loxo elbows its way back into the ASCO spotlight with 2nd tissue-agnostic cancer drug success [EndPoints]

Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an ASCO stampede [EndPoints]

Loxo Oncology posts improved results for newest cancer drug [Reuters] ASCO (médecine de précision-sein)

TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy [NCI]

Breast cancer gene test could spare some women chemo [Cancer Research UK]

Many breast cancer patients can skip chemo, big study finds [STAT]

Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test [ASCO]

For Some Breast Cancer Patients, The Chemo Decision Just Got Easier [NPR]

Many Breast Cancer Patients Can Safely Skip Chemo, Large Trial Confirms [Forbes]

Thousands of breast cancer patients could avoid chemo, study finds [The Guardian]

Good News for Women With Breast Cancer: Many Don’t Need Chemo [NY Times]

5.5.18 ASCO (observation)

Study Finds Gender Disparities in Head and Neck Cancer Treatment and Outcomes [ASCO]

5.5.19 ASCO (rein)

Some people with advanced kidney cancer could avoid surgery [Cancer Research UK]

Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery [ASCO]

5.5.2 ASCO (sein)

Myriad Genetics Presents Second Pivotal Validation Study for riskScore™ Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting [Myriad]

Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer [Novartis]

New Targeted Therapy Slows Growth of Advanced Breast Cancer [ASCO]

Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer [EndPoints]

5.5.3 ASCO (prostate)

Abiraterone May Be More Effective in Black Men With Advanced Prostate Cancer Than in White Men [ASCO]

5.5.4 ASCO (immunothérapies)

Antibiotics greatly reduce effectiveness of cancer treatment – study [The Guardian] ASCO (immunothérapies-combinaisons)

Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018 [BMS]

Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study [BMS]

A controversial ASCO presentation underscores risk Bristol, Nektar carry with experimental cancer drug [STAT]

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug [Forbes]

Roche drugs show limited benefit in lung, breast cancer trials [Reuters]

Mixed results for Bristol/Nektar combination in cancer trial [Reuters] ASCO (immunothérapies-prostate)

Immunotherapy could stop prostate cancer spreading, trial shows [The Guardian] ASCO (immunothérapies-poumon)

Adding Atezolizumab Immunotherapy to Chemotherapy Slows Growth of Advanced Squamous Lung Cancer [ASCO]

Immunotherapy Pembrolizumab Works Better Than Chemotherapy Alone as Initial Treatment for Most Advanced Lung Cancers [ASCO]

Merck Wins Again [Forbes]

Roche boasts of stalling lung cancer with Tecentriq/chemo combo — but rival Merck stays out front [EndPoints]

Merck’s Keytruda builds a commanding lead in frontline lung cancer with data from two more landmark trials [EndPoints]

Merck's Keytruda extends lung cancer survival in two trials [Reuters] ASCO (immunothérapies-CAR-T)

Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting [bluebirdbio]

#ASCO18: Bluebird & Celgene’s CAR-T nears 1 year of PFS in multiple myeloma [FierceBiotech]

Bluebird Bio CAR-T delays multiple myeloma progression by one year, but is that enough? [STAT]

Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet [Forbes]

Bluebird, Celgene add a promising chapter to their success story with BCMA-targeting CAR-T — but fall short for investors [EndPoints]

Bluebird myeloma treatment delays cancer progression: trial [Reuters]

5.5.9 ASCO (autres organes)

Maintenance Chemotherapy Extends Life for Children With a Rare Cancer – First Treatment Advance for This Cancer in 30 Years [ASCO]